Blog
RSS FeedPosted by Michael Wonder on 10 May 2022
Calls for Health Minister to release final report from PHARMAC review
11 May 2022 - Health Minister Andrew Little is facing calls to release the final report from a review of ...
Posted by Michael Wonder on 09 May 2022
Next Health Minister must restart the National Medicines Policy Review
10 May 2022 - Medicines Australia has released a video outlining the importance of restarting the National Medicines Policy Review ...
Posted by Michael Wonder on 06 May 2022
Congress moves toward reforming FDA accelerated approvals, but with pharma friendly concessions
4 May 2022 - House lawmakers are moving a little closer toward cracking down on drugmakers that game the FDA’s ...
Posted by Michael Wonder on 02 May 2022
What is the HTA review and why is it important for Australia’s health system?
3 May 2022 - Medicines Australia has released its fourth video in its Federal Election series, explaining the upcoming independent ...
Posted by Michael Wonder on 12 Apr 2022
It’s time to fix the FDA by breaking it up
11 April 2022 - A new investigation about the agency’s failures underscores the need for a separate agency to keep our ...
Posted by Michael Wonder on 10 Apr 2022
Health Technology Assessment Review Reference Committee will drive reform to support Australian patients
10 April 2022 - The Health Technology Assessment Review Reference Committee announced (via the Department of Health website) is tasked ...
Posted by Michael Wonder on 09 Apr 2022
Life Saving Drugs Program – medicines reviews recommendations
7 April 2022 - This document outlines 51 recommendations from the Life Saving Drugs Expert Panel review. ...
Posted by Michael Wonder on 07 Apr 2022
ICER publishes white paper evaluating reforms to orphan drug development, pricing and coverage
7 April 2022 - The white paper presents an analysis of the potential risks and benefits of reforms seeking to ...
Posted by Michael Wonder on 05 Apr 2022
Consultation now open - review of base case discount rate at 3A.1 of the PBAC Guidelines
5 April 2022 - The Commonwealth has entered into a new Strategic Agreement in relation to reimbursement, health technology assessment ...
Posted by Michael Wonder on 25 Mar 2022
DUSC utilisation analysis public release documents
25 March 2022 - The utilisation analysis public release documents from the October 2021 DUSC meeting are now available. ...
Posted by Michael Wonder on 23 Mar 2022
Government opts for additional consultation on National Medicines Policy review
24 March 2022 - The Government has heeded the calls from Medicines Australia, patient groups, health bodies, and industry by ...
Posted by Michael Wonder on 17 Mar 2022
Panel scrutinises quick FDA drug approvals
17 March 2022 - A House committee will spotlight an FDA process that’s been criticised as putting some of the ...
Posted by Michael Wonder on 03 Mar 2022
PRIME enables earlier availability of life-changing medicines
3 March 2022 - EMA’s PRIority Medicines (PRIME) scheme has had a positive impact on the authorisation of new medicines that ...
Posted by Michael Wonder on 21 Feb 2022
Responses to Prostheses List reform
16 February 2022 - Consultation paper #3 A modernised fit for purpose listing process was released on 11 January and closes ...
Posted by Michael Wonder on 15 Feb 2022
Office of Generic Drugs 2021 Annual Report
14 February 2022 - Ensuring high quality, affordable generic drugs are available to the American public. ...